Also updated at the American Diabetes Association conference in Chicago was the MiniMed Integrated System device, which doctors are reporting as a major step toward an "artificial pancreas." The device constantly monitors blood sugar and automatically supplies insulin as needed.
Associated Press/October 2012 image from Medtronic
About this Article
Patients taking Eli Lilly & Co.ís experimental diabetes drug dulaglutide lost weight and had side effects that were manageable, the company said today after releasing more data from three final-stage clinical trials.